Find comprehensive information on Prostate Cancer with Bone Metastases, including clinical documentation, medical coding, ICD-10 codes C61 and C79.51, treatment options, prognosis, and support resources. Learn about bone scan interpretations, PSA levels in metastatic prostate cancer, and the role of healthcare professionals in managing this advanced stage of prostate cancer. Explore the latest research and guidelines for accurate diagnosis and optimal patient care.
Also known as
Malignant neoplasm of prostate
Cancer originating in the prostate gland.
Secondary malignant neoplasm of bone
Cancer that has spread to the bones from the prostate.
Personal history of malignant neoplasm of prostate
Indicates a past diagnosis of prostate cancer, now with bone metastases.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the prostate cancer documented as primary?
When to use each related code
| Description |
|---|
| Prostate cancer with bone metastases |
| Prostate cancer with other metastases |
| Metastatic cancer to bone, primary unknown |
Coding bone mets without specifying the affected bones leads to under-reporting severity and potential DRG downcoding impacting reimbursement.
Inaccurate staging of prostate cancer (e.g., missing clinical/pathological TNM) impacts treatment planning and accurate risk adjustment.
Miscoding primary bone malignancy as prostate cancer with bone mets results in inaccurate reporting and skewed cancer registry data.
Patient presents with complaints consistent with metastatic prostate cancer to the bone. Symptoms include persistent bone pain, particularly in the spine and pelvis, along with fatigue and decreased mobility. Physical examination reveals point tenderness in the affected areas. Laboratory results demonstrate an elevated prostate-specific antigen (PSA) level, confirming the suspicion of prostate cancer. Bone scan imaging reveals multiple osteoblastic lesions indicative of bone metastases. Diagnostic criteria for prostate cancer with bone metastases have been met based on the combination of clinical findings, elevated PSA, and positive bone scan. The patient's diagnosis is prostate cancer with bone metastases (ICD-10 C61, C79.51). Treatment plan will be discussed with the patient and may include androgen deprivation therapy (ADT), radiation therapy for pain management, bisphosphonates for skeletal-related events prevention, and consideration for chemotherapy or newer hormonal agents. The patient's prognosis and treatment options were discussed, including palliative care options for symptom management. Follow-up appointment scheduled to monitor treatment response and address any emerging complications. Differential diagnoses considered included benign prostatic hyperplasia (BPH), prostatitis, and other bone pathologies. This documentation supports medical coding for prostate cancer, bone metastases, and associated treatment procedures. Prognosis, treatment response, and potential adverse effects will continue to be monitored.